- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03374345
Efficacy and Safety of Sipjeondaebo-tang on Korean Patients With Cold Hypersensitivity in the Hands and Feet (SDT)
August 30, 2021 updated by: Chan-Yong Jeon, Gachon University Gil Oriental Medical Hospital
Gachon University, Gil Oriental Medicine Center
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Incheon, Korea, Republic of
- Gachon University Gil Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 59 years (ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Female subjects aged 19 to 59 years have a complaint of CHH.
- Patients must include at least one or more of the following symptoms:
- Those who have the symptoms of CHH in normal temperature which most individuals feel no cold;
- Those who have the symptoms of extremely cold hands in cold temperature exposure;
- Those who are on the return to a warmer environment, the symptoms of cold hands is not completely rewarmed;
- Those who have 4 cm or greater of VAS CHH score;
- A thermal differences between the palm (PC8) and the upper arm (LU4) may be higher than 0.3℃;
- Those who can comply with all study-related procedures, medications, and evaluations;
- Given a written informed consent form.
Exclusion Criteria:
- Patients with calcium antagonists or beta-blockers with the purpose of treating CHH;
- Those who have one or more finger gangrene or ulceration;
- Those who are diagnosed by hypothyroidism or currently medicated to thyroid drugs;
- Those who are diagnosed by autoimmune disease or have a positive ANA test result;
- Those who are diagnosed by carpal tunnel syndrome or have a positive Tinel and Phalen's tests;
- Those who are diagnosed with cervical disc herniation or (malignant) tumor disease;
- Those who are diagnosed with diabetes;
- Those who are currently medicated to drugs that may affect to CHH symptoms, such as anticoagulants etc;
- Those who have moderate level of liver dysfunction (each of AST, ALT greater than 100 IU/L) or kidney dysfunction (Cr 2.0mg/dL);
- Those who do not (cannot) abide by treatment and follow up due to the mental illness such as behavior disorder, depression, anxiety neurosis, schizophrenia, or serious mental illness;
- Those who are Diagnosed with moderate anemia and hematologic disorders (adult non-pregnant women hemoglobin (Hgb) level less than 7g/dL, hematocrit (Hct) level less than 26%, white blood cell (WBC) level greater than 11,000/mm3); Those whose systolic blood pressure (SBP) 180mmHg or diastolic blood pressure (DBP) is greater than 100 mmHg based on average value of at least 2 measurements;
- Those who are suspected arrhythmia that showing up on ECG, or diagnosed by heart diseases, such as, ischemic heart disease and so on;
- Those who are addicted to alcohol or drugs;
- Those who are pregnant (positive urine-HCG) or lactating or have the chances of pregnancy;
- Those who are diagnosed with malignant tumor
- Those who are currently participated in other clinical trials;
- Those who are able to understand and speak Korean;
- Those who are judged to be inappropriate for the clinical study by the researchers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: SDT group
3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
|
3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
Other Names:
|
PLACEBO_COMPARATOR: Placebo group
3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
|
3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in visual analogue scale(VAS)
Time Frame: At baseline, week 4, 8, 12
|
The visual analog scale for pain is a straight line with one end meaning no pain and the other end meaning the worst pain imaginable.
A patient marks a point on the line that matches the amount of pain he or she feels.
|
At baseline, week 4, 8, 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline in body temperature
Time Frame: At baseline, week 4, 8, 12
|
Changes from baseline in body temperature
|
At baseline, week 4, 8, 12
|
Changes from baseline in WHO Quality of Life-BREF
Time Frame: At baseline, week 4, 8, 12
|
It is a international cross-culturally comparable quality of life assessment instrument.
The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment.
There are also two items that are examined separately: Q1 asks about an individuals overall perception of QoL and Q2 asks about an individuals overall perception of their health.
The four domain scores denote an individuals perception of QoL in each particular domain.
Domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).
The mean score of items within each domain is used to calculate the domain score.
Meanscores are then multiplied by 4 in order to make domain scores comparable with the scores used in the WHOQOL-100.
|
At baseline, week 4, 8, 12
|
Changes from baseline in blood pressure
Time Frame: up to 12 weeks
|
assess for monitoring patient safety
|
up to 12 weeks
|
Changes from baseline in Pulse rate
Time Frame: up to 12 weeks
|
assess for monitoring patient safety
|
up to 12 weeks
|
Levels of AST
Time Frame: At screening visit, week 8
|
liver function test for monitoring patient safety(IU/L)
|
At screening visit, week 8
|
Levels of ALT
Time Frame: At screening visit, week 8
|
liver function test for monitoring patient safety(IU/L)
|
At screening visit, week 8
|
Levels of r-GTP
Time Frame: At screening visit, week 8
|
liver function test for monitoring patient safety(IU/L)
|
At screening visit, week 8
|
Levels of BUN
Time Frame: At screening visit, week 8
|
Kidney function test for monitoring patient safety(mmol/L)
|
At screening visit, week 8
|
Levels of Cr
Time Frame: At screening visit, week 8
|
Kidney function test for monitoring patient safety(mmol/L)
|
At screening visit, week 8
|
complete blood count
Time Frame: At screening visit, week 8
|
At screening visit, week 8
|
|
Adverse event
Time Frame: At week 4, 8, 12
|
At week 4, 8, 12
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pattern Identification Questionnaire
Time Frame: At screening visit
|
This tool is a traditional medicine researcher self-developed questionnaire of screening for patients with Cold Hypersensitivity in the Hands and feet In this trial, we will assess the validity of the tool.
|
At screening visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
January 31, 2018
Primary Completion (ACTUAL)
December 30, 2019
Study Completion (ACTUAL)
December 30, 2019
Study Registration Dates
First Submitted
November 27, 2017
First Submitted That Met QC Criteria
December 13, 2017
First Posted (ACTUAL)
December 15, 2017
Study Record Updates
Last Update Posted (ACTUAL)
September 1, 2021
Last Update Submitted That Met QC Criteria
August 30, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISEE_2017_SDT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cold Hypersensitivity
-
Charite University, Berlin, GermanyCompletedAcquired Cold UrticariaGermany
-
Third Harmonic Bio, Inc.TerminatedChronic Cold UrticariaNetherlands, Germany
-
Celldex TherapeuticsCompletedCold Urticaria | Symptomatic Dermographism | Cholinergic Urticaria | Cold Contact Urticaria | Symptomatic DermatographismGermany
-
Regeneron PharmaceuticalsCompletedGenetic Diseases, Inborn | Familial Cold Autoinflammatory Syndrome (FCAS) | Familial Cold Urticaria | Muckle-Wells Syndrome (MWS)United States
-
Marcus MaurerJohannes Gutenberg University MainzCompleted
-
SanofiRegeneron PharmaceuticalsCompletedCold UrticariaUnited States, Argentina, Canada, Germany, Japan
-
Charite University, Berlin, GermanyRegeneron PharmaceuticalsCompleted
-
Charite University, Berlin, GermanyHospital del MarCompletedCold Contact UrticariaGermany
-
Charite University, Berlin, GermanyFaes Farma, S.A.CompletedCold Contact UrticariaGermany
-
Charite University, Berlin, GermanyNovartis PharmaceuticalsCompleted
Clinical Trials on Sipjeondaebo-tang Granule
-
Kyunghee University Medical CenterCatholic Kwandong UniversityUnknownBreast CarcinomaKorea, Republic of
-
Shanghai University of Traditional Chinese MedicineUnknownHeart Failure With Preserved Ejection FractionChina
-
Gachon University Gil Oriental Medical HospitalDaejeon University; Semyung University Korean Medicine Hospital in Chungju; Woosuk...RecruitingChronic Low Back PainKorea, Republic of
-
Gachon University Gil Oriental Medical HospitalDongGuk University; Sangji University Oriental Medical Hospital, KoreaCompleted
-
Kyung Hee University Hospital at GangdongCompletedRespiratory Tract Diseases | Nose Diseases | RhinitisKorea, Republic of
-
Gachon University Gil Oriental Medical HospitalKyung Hee University Hospital at Gangdong; DongGuk University; Kyunghee University... and other collaboratorsCompletedCold HypersensitivityKorea, Republic of
-
Henan University of Traditional Chinese MedicineUnknownPulmonary Disease, Chronic Obstructive
-
Korea Health Industry Development InstituteUnknown
-
Guang'anmen Hospital of China Academy of Chinese...Tasly Pharmaceuticals, Inc.Completed
-
Henan University of Traditional Chinese MedicineUnknown